MRUS
Source profileMerus
Bispecific antibodies
Company profile
CIK1651311
ExchangeNASDAQ
SectorHealthcare
Tracked assets1
Pipeline assets
Petosemtamab
Head and neck cancer
Phase 2Phase 2 Readout
Upcoming and past catalysts
| Company | Catalyst | Asset | Phase | Expected | Confidence | Status |
|---|---|---|---|---|---|---|
| MRUS Merus | Combination cohort clinical update Phase 2 Readout | Petosemtamab | Phase 2 | Q4 2026 | quarter | upcoming |
SEC filings
No sample filings for this company.
Press releases
No sample press releases for this company.
ClinicalTrials.gov studies
Change history
No sample changes yet.